Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects With HPV Positive Cancers

NCT04432597 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04432597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04432597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects With HPV Positive Cancers
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Completed
Start date
August 11, 2020
Completion date
March 31, 2026
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, cervical cancer, hpv positive cancer, oropharyngeal cancer, vulvar, vaginal, penile, rectal cancer